New Regulatory Opportunity for Generic Essential Medicines in Singapore

In January 2026, HSA introduced a new pathway for certain generic drugs that have been used in Singapore’s clinical settings for years but do not have a corresponding registered reference product in Singapore.

For overseas companies holding mature generic portfolios or essential medicines, this may potentially create new opportunities to evaluate Singapore market entry possibilities which may not have been considered previously.

This is not a shortcut registration pathway and HSA’s quality, safety and efficacy expectations would still apply. However, from a regulatory strategy perspective, the pathway may remove one of the key barriers which historically prevented some overseas generic products from being considered for registration in Singapore.

What Products May Qualify?

Under HSA’s guidance, several key criteria would generally need to be fulfilled.

Well-established safety and efficacy

The product should demonstrate established safety and efficacy supported by recognised references and pharmacopoeial standards. This pathway is intended for medicines with long-standing clinical use rather than innovative or newly developed products.

Documented clinical use in Singapore

The active ingredient, dosage form and strength should either be listed on the Ministry of Health (MOH) Standard Drug List (SDL) or have been included on a public healthcare institution’s Pharmacy & Therapeutics (P&T) list for at least five years prior to submission.

No corresponding Singapore reference product

Products with an existing corresponding Singapore reference product would generally not qualify under this pathway, as the standard generic registration route would remain applicable.

For companies exploring the standard registration route for generics in Singapore, you may also wish to read our article on Generic Drug Application requirements and common regulatory considerations in Singapore.

In addition, HSA would also expect the product to demonstrate acceptable quality standards, overseas regulatory history and no known significant global safety concerns.

The Expression of Interest (EOI) Comes First

Before submitting a full Generic Drug Application (GDA), applicants are required to submit an Expression of Interest (EOI) to HSA at least three months before the intended submission date.

The EOI should clearly justify the product’s eligibility under the pathway together with its local clinical relevance and supporting product background.

From a practical perspective, this step is important as HSA would first assess whether the product is suitable to proceed under the pathway before the formal submission is made.

Why This May Matter for Overseas Generic Companies

From experience, one of the common assumptions among overseas generic companies is that products without a corresponding Singapore reference product are generally not suitable for registration locally.

As a result, some mature generic portfolios may never have been assessed for Singapore registration opportunities despite having established overseas use and supporting clinical history.

This pathway may therefore be relevant for companies holding:

Mature generic medicines with long-standing overseas market history;
Essential medicines supplied to hospital settings;
Products already used within public healthcare systems overseas;
Generic portfolios intended for ASEAN market expansion.

However, one of the common challenges is that many dossiers were originally prepared for other markets and may not fully align with Singapore regulatory expectations from the beginning.

In practice, companies may still need to assess:

Whether the product genuinely fulfils the eligibility criteria;
Availability of acceptable supporting literature and pharmacopoeial standards;
Alignment of the dossier against HSA expectations;
Whether additional bridging or bioequivalence justification may still be required;
Suitability of the proposed indication and product positioning.

The key issue is often not simply whether the product may potentially fit the pathway, but whether the available supporting package is sufficiently aligned with HSA’s expectations before submission planning starts.

How TRC Can Support

TRC supports overseas pharmaceutical companies with Singapore regulatory strategy, product registration and lifecycle management activities. For companies exploring whether their products may potentially fit this pathway, TRC can support with early product assessment, regulatory gap review, EOI preparation and overall submission planning based on the product profile and available supporting data.

In many situations, an initial assessment is usually sufficient to determine whether the pathway may realistically be feasible and what areas may require further preparation before proceeding with submission activities.

If your company is currently evaluating Singapore market entry opportunities for mature generic or essential medicine portfolios, feel free to contact TRC for an initial discussion.

Back To Blog